Acclarent, maker of medical devices to treat ear, nose and throat conditions, has become the latest biotech firm to withdraw its IPO due to poor market conditions. It originally filed in June, hoping to bring in $86.3 million to expand marketing and sales activities.

The Menlo Park, Calif. company’s chief financial officer, George Harter, told VentureWire that it will be keeping its eye on the situation, but said he didn’t expect the IPO market to thaw enough for another try until late 2009 or 2010.

Acclarent last raised funds in 2007, bringing in $35 million in third-round funding from Delphi Ventures, Meritech Capital Partners, Versant Ventures and New Enterprise Associates — which has the highest stake in the company at 44.5 percent.

The biotech firm follows in the footsteps of Xanodyne and ChemoCentryx in cancelling its plans to go public. The IPO window has been slammed particularly tight for companies in this sector.

VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative enterprise technology and transact. Learn more about membership.